

301
Abstract (Basic): FR 2092875 A

The liberation and formation of interferon is stimulated by complexes prepared from (a) a mono-bi- or tri-catenary nucleic acid or similar cpd. contg. anionic reactive centres and (b) a dialkylaminoalkyl dextran or other polymer having cationic reactive centres. In an example a heteropolymer of adenine and uracil was complexed with diethylaminoethyl dextran, protamine, histone, hexadimethrin bromide, polyornithine polylysine and lysozyme. All of these complexes protected mice against a lethal dose of virus.

? S PN=FR 2719316

S11 1 PN=FR 2719316

? T 11/3,AB/1

11/3,AB/1

DIALOG(R) File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

010474297

WPI Acc No: 1995-375617/*199549*

XRAM Acc No: C95-162667

New nucleic acid complexes with cationic polymers - useful for genetic transformation of cells.

Patent Assignee: IDM IMMUNO-DESIGNED MOLECULES (IDMI-N)

Inventor: ERBACHER P; MIDOUX P; MONSIGNY M; ROCHE-DEGREMONT A

Number of Countries: 065 Number of Patents: 010

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
FR 2719316	A1	19951103	FR 945174	A	19940428	199549 B
WO 9530020	A1	19951109	WO 95FR535	A	19950424	199550
AU 9524128	A	19951129	AU 9524128	A	19950424	199609
EP 753070	A1	19970115	EP 95918049	A	19950424	199708
			WO 95FR535	A	19950424	
US 5595897	A	19970121	US 94288681	A	19940810	199710
US 5733762	A	19980331	US 94288681	A	19940810	199820
			US 95505068	A	19950721	
			US 96741678	A	19961031	
AU 695056	B	19980806	AU 9524128	A	19950424	199843
EP 753070	B1	20020925	EP 95918049	A	19950424	200271
			WO 95FR535	A	19950424	
DE 69528363	E	20021031	DE 628363	A	19950424	200279
			EP 95918049	A	19950424	
			WO 95FR535	A	19950424	
ES 2181775	T3	20030301	EP 95918049	A	19950424	200322

Priority Applications (No Type Date): FR 945174 A 19940428

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

FR 2719316	A1		58	C12N-015/11	
------------	----	--	----	-------------	--

WO 9530020	A1 F		78	C12N-015/87	
------------	------	--	----	-------------	--

Designated States (National): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ UG

AU 9524128	A		C12N-015/87	Based on patent WO 9530020
------------	---	--	-------------	----------------------------

EP 753070	A1 F		C12N-015/87	Based on patent WO 9530020
-----------	------	--	-------------	----------------------------

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

US 5595897 A 24 C07K-001/00
US 5733762 A 54 C07K-001/00 CIP of application US 94288681
CIP of application US 95505068
CIP of patent US 5595897
AU 695056 B C12N-015/87 Previous Publ. patent AU 9524128
Based on patent WO 9530020
EP 753070 B1 F C12N-015/87 Based on patent WO 9530020
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE
DE 69528363 E C12N-015/87 Based on patent EP 753070
Based on patent WO 9530020
ES 2181775 T3 C12N-015/87 Based on patent EP 753070

Abstract (Basic): FR 2719316 A

Complexes (I) of negatively charged nucleic acids (II) with positively charged polymers (III) are claimed, where: (a) the bond between (II) and (III) is electrostatic; (b) (III) comprises monomer units bearing NH₃⁺ gps. (c) at least 10% of the NH₃⁺ gps. are replaced by uncharged amino gps. bearing a substit. that has at least one OH gp. and is not recognised by cell membrane receptors; and (d) the NH₃⁺ and/or OH gps. may be substd. by a gp. that is recognised by a cell membrane receptor, provided that at least 30% of the NH₃⁺ gps. remain free.

USE - (I) or (III) are esp. useful for transfecting haematopoietic cells, skeletal muscle cells, fibroblasts, keratinocytes, dendritic cells, melanocytes, vascular endothelial cells, vascular smooth-muscle cells, airway epithelial cells, CNS cells, cancer cells and immune system cells. (I) or (III) can also be used to prepare a medicament intended, e.g., for treatment of congenital or acquired metabolic deficiencies or tumours or for prepn. of vaccines, e.g. against influenza.

Dwg.0/7

Abstract (Equivalent): US 5595897 A

A compound consisting of polylysine conjugated to noncharged residues wherein the free amino functions of said polylysine are substituted with said non-charged residues, which non-charged residues comprise gluconolactone, and said conjugated polylysine contains at least 30% unsubstituted free amino functions, is new.

Dwg.0/7

? S PN=GB 2038628

S12 1 PN=GB 2038628

? S S12 AND LA=ENGLISH

1 S12

0 LA=ENGLISH

S13 0 S12 AND LA=ENGLISH

? T 12/3,AB/1

12/3,AB/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

002535948

WPI Acc No: 1980-53974C/*198031*